Last reviewed · How we verify
Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients
Approved treatments
- Famvir · Novartis
Famvir works by inhibiting the replication of herpes simplex virus DNA through its action as a nucleoside analog DNA polymerase inhibitor.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients patent landscape — cliff calendar, originator estates, attackable patents
- Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients treatment landscape brief
- Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients treatment updates RSS
Frequently asked questions about Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients
What drugs treat Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients?
Tracked treatments include Famvir.
What is the treatment for Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients?
Standard treatment for Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients includes Famvir. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients patent cliff · Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients CI report
- Treatment: Famvir · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing